Sign Out
Women of childbearing potential: Women of childbearing potential should avoid pregnancy for at least one month following vaccination. Women who intend to become pregnant should be advised to delay.
Pregnancy: Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see Pharmacology: Toxicology: Nonclinical Safety Data under Actions).
There is limited amount of data from the use of Qdenga in pregnant women. These data are not sufficient to conclude on the absence of potential effects of Qdenga on pregnancy, embryo-fetal development, parturition and post-natal development.
Qdenga is a live attenuated vaccine, therefore Qdenga is contraindicated during pregnancy (see Contraindications).
Breast-feeding: It is unknown whether Qdenga is excreted in human milk. A risk to the newborns/infants cannot be excluded.
Qdenga is contraindicated during breast-feeding (see Contraindications).
Fertility: Animal studies did not indicate any harmful effects with respect to female fertility (see Pharmacology: Toxicology: Nonclinical Safety Data under Actions). No specific studies have been performed on fertility in humans.
